Sanofi (SNY +1.1%) tetravalent drug, potentially the world's first vaccine against dengue fever,...


Sanofi (SNY +1.1%) tetravalent drug, potentially the world's first vaccine against dengue fever, provided protection against 3 of the virus' 4 strains in a Phase IIb study in Thailand. Dengue fever is spread by mosquitoes and is a threat to almost 3B people; if tetravalent is approved, Sanofi reckons annual sales could top $1B. A Phase III trial is already under way. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs